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Uptake of apoptotic cells (ACs) by dendritic cells
(DCs) and induction of a tolerogenic DC pheno-
type is an important mechanism for establishing
peripheral tolerance to self-antigens. The receptors
involved and underlying signaling pathways are not
fully understood. Here, we identify Dectin-1 as a
crucial tolerogenic receptor binding with nanomolar
affinity to the core domain of several annexins
(annexin A1, A5, and A13) exposed on ACs.
Annexins bind to Dectin-1 on a site distinct from
the interaction site of pathogen-derived b-glucans.
Subsequent tolerogenic signaling induces selective
phosphorylation of spleen tyrosine kinase (SYK),
causing activation of NADPH oxidase-2 and moder-
ate production of reactive oxygen species. Thus,
mice deficient for Dectin-1 develop autoimmune
pathologies (autoantibodies and splenomegaly)
and generate stronger immune responses (cytotoxic
T cells) against ACs. Our data describe an important
immunological checkpoint system and provide a link
between immunosuppressive signals of ACs and
maintenance of peripheral immune tolerance.
INTRODUCTION
Removal of apoptotic cells (ACs) is closely associatedwith the in-
duction of immunological self-tolerance. Each day, billions of
ACs are phagocytosed by antigen-presenting cells such as den-
dritic cells (DCs) and actively modulate the immune response
(Vaux and Korsmeyer, 1999). Following engulfment of ACs,
DCs acquire a tolerogenic phenotype characterized by low
expression of co-stimulatory surface molecules and inflamma-
tory cytokines as well as resistance to activation (Morelli andCell Repor
This is an open access article undThomson, 2007). These tolerogenic DCs process AC-derived
self-antigens and present them to naive T cells, thereby inducing
T cell tolerance (Voll et al., 1997; Tanaka et al., 2008; Mueller,
2010). While phagocytic receptors and their ligands on ACs are
well described (Arandjelovic and Ravichandran, 2015), less is
known about the tolerogenic signaling machinery engaged by
ACs. Recently, we demonstrated that early ACs expose mem-
bers of the annexin protein family on their surface (Weyd et al.,
2013) that bind to negatively charged phospholipids such as
phosphatidylserine (PS) in a Ca2+-dependent manner (Gerke
and Moss, 2002). It is well established that annexin A1 serves
as an inhibitory signal to DCs and facilitates the development of
peripheral tolerance (Yang et al., 1999; Pupjalis et al. 2011;Blume
et al. 2009; Perretti and Dalli, 2009;Weyd et al., 2013; Linke et al.,
2015). Structurally, all annexin family members contain an evolu-
tionary conserved core domain and auniqueN terminus. Immune
regulatory functions such as neutrophil extravasation have
mainly been described for annexin A1 and have been attributed
toN-terminal binding to theN-formyl peptide receptor (FPR) fam-
ily (Walther et al., 2000; Perretti et al., 2001). However, we found
that the tolerogenic function mediated by the conserved annexin
core domain is independent of FPRs (Linke et al., 2015). Specific
receptors binding to the annexin core domain and mediating its
tolerogenic effects remained elusive.
Dectin-1 (also known as Clec7a) belongs to the C-type lectin re-
ceptor (CLR) superfamily expressed on DCs, macrophages, and
other immune cells. It serves as a pattern-recognition receptor
withhighaffinity tob-1,3-linkedglucans (b-glucans) (e.g., zymosan)
present in cell walls of fungal and bacterial species. Thus, Dectin-1
is involved in the activation of immune responses following micro-
bial and fungal infections (Plato et al., 2013; Dambuza and Brown,
2015; Brown et al., 2018). The induction of Dectin-1 signaling
mainlydependson the tyrosine-basedhemi-immunoreceptor acti-
vation motif in its cytoplasmic region, activating pathways through
spleen tyrosine kinase (SYK), Raf-1, and Card-9. In addition,
Dectin-1 stimulation by b-glucans leads to the downstream activa-
tion of nuclear factor kappa-light-chain-enhancer of activatedts 29, 4435–4446, December 24, 2019 ª 2019 The Author(s). 4435
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. The Conserved Annexin Core
Domain Is Recognized by Dectin-1 at Sites
Distinct from b-Glucan-Binding Sites
(A and B) Murine annexin A1 (mAnxA1) (A), the core
domain of annexin A1 (mAnxA1DN) (B), mAnxA5
(A and B), and depleted zymosan (DZ) or BSA (B)
were immobilized and incubated with the indicated
self-produced C-type lectin receptor (CLR) fusion
proteins (A) or a commercially available mDectin-1
Fc (B).
(C) Interaction of purified human annexin A1DN
(hAnxA1DN) (upper left and upper right panel) and
annexin-A1DN-coated phosphatidylserine (PS)
vesicles (PSV-Anx; lower left and lower right panel)
with human Dectin-1 (hDectin-1)-expressing and
Dectin-1 KO Mono Mac 6 (MM6) cells analyzed by
quartz crystal microbalance technology. Both cell
typeswere immobilized on Attana sensor surfaces.
The signal output given in frequency (Hz) is directly
related to changes in mass on the sensor surface
(see STAR Methods).
(D) Characteristic binding responses of filtrated DZ
(%400 nm) and PSV-Anx to hDectin-1-expressing
MM6 cells. The maximum binding capacity (Bmax)
value indicates the ligand specific frequency of
fully saturated cell-surface binding (DZ 7 Hz,
PSV-Anx 15 Hz).
(E) First, PSV-Anx was applied to the immobilized
cells several times (red arrows; increasing
amounts from left to right: 1:30, 1:25, 1:20, 1:15,
and 1:10) until full binding response of PSV-Anx
(15 Hz) to the cell surface was obtained (also see
STAR Methods). Next, a mixture of DZ and PSV-
Anx was applied several times in same ratios
(black arrows; increasing amounts from left to
right: 1:30, 1:25, 1:20, 1:15, and 1:10) to investigate
the occurrence of additional binding. PC, phos-
phatidylcholine. Results are representative of two
independent experiments.
See also Figures S1 and S3 and Table S1.B cells (NF-kB), among other signaling pathways (Scha¨ppi et al.,
2008; Reid et al., 2009; Dambuza and Brown, 2015).
In this study, we describe an immunosuppressive signaling
pathway of ACs mediated by externalized annexins binding to
Dectin-1. This receptor-ligand interaction constitutes an essen-
tial mechanism of peripheral immune tolerance by inducing a
tolerogenic DC-phenotype in response to ACs.
RESULTS
The C-type Lectin Receptor Dectin-1 Binds to the
Conserved Annexin Core Domain
Wepreviously demonstrated that several annexin familymembers
(annexinA1,A5, andA13) inhibit DCactivationand induceantigen-
specificCD8+ T cell tolerance in vivowhenexposed on the surface
ofACs (Weydetal., 2013; Linke et al., 2015). This immunosuppres-
sive activity of annexins was confined to the conserved annexin
coredomainandwasnotmediatedbymembers of the FPR family,
which bind to the unique annexin A1 N terminus (Walther et al.,
2000;Perretti et al., 2001; Linkeetal., 2015). In search for a specific
receptor binding to several annexin family members, we per-
formed in vitrobindingexperiments usingCLR-fragmentcrystalliz-4436 Cell Reports 29, 4435–4446, December 24, 2019able (Fc) library and recombinant annexins A1 and A5. Of all CLRs
tested, we observed strong binding of both annexins to Dectin-1
only (Figure 1A). Since all annexin family members share the an-
nexin core domain, these data suggest that Dectin-1 binds to the
conserved core domain of various annexin family members. We
confirmed the specific binding of Dectin-1 to the annexin A1
core domain by using a truncated version of annexin A1 (annexin
A1DN) that lacks the N terminus (Figures 1B and S1A). Moreover,
Fc-receptor-based surface plasmon resonance (SPR) experi-
ments showed high-affinity binding of Dectin-1 to all annexins
tested (annexin A1, annexin A1DN, annexin A5, and annexin
A13; Figures S1B–S1F). We also confirmed the binding of Dec-
tin-1 to annexins exposed on the surface of ACs (Figure S1G;
Weck et al., 2008).
In order to investigate the Dectin-1/annexin interaction in a
physiological context, we performed cell-based affinity mea-
surements using quartz crystal microbalance (QCM) technology
(see STAR Methods; Peiris et al., 2017; Salanti et al., 2015). We
used stably transfected Dectin-1-expressingMonoMac 6 (MM6)
cells as well as CRISPR-Cas9-mediated Dectin-1 knockout (KO)
MM6 cells (Figures S2A–S2C; Ziegler-Heitbrock et al., 1988; Ran
et al., 2013) and soluble recombinant annexin A1DN and annexin
A5 as ligands. A Dectin-1-specific antibody and the Dectin-1
ligand depleted zymosan (DZ) served as positive controls. As
expected, we observed increased binding of annexins to
Dectin-1-expressing MM6 cells compared to the Dectin-1 KO
MM6 cells (Figure 1 C; Table S1). However, we also detected
high background binding to Dectin-1 KOcells, possibly due to in-
teractions with negatively charged phospholipids such as PS
exposed at low levels on the cell surface of living phagocytes
(Callahan et al., 2000, 2003). To prevent background binding of
annexins to PS, we generated defined PS-containing lipid vesi-
cles and loaded them with annexin A1DN (Figure S2D). This
way, the receptor-binding interface of annexin, as present on
ACs, was still available for receptor interaction, while the
PS-binding sites were occupied. Using annexin-coated lipid
vesicles, we could demonstrate exclusive binding to Dectin-1-
expressing MM6 cells (Figure S3B). Based on these results we
conclude that Dectin-1 is a specific receptor for the PS-bound
core domain of annexin A1 and other annexin family members.
To extend these data, we performed competitive QCM experi-
ments to investigate whether annexins share the same binding
site with classical pathogen-derived Dectin-1 ligands such as
DZ. These experiments confirmed the exclusive binding of
vesicle-bound annexin A1DN to Dectin-1-expressing MM6 cells
(Figure 1C). We first determined the specific change of frequency
for saturation of both ligands (15.1 Hz for annexin A1DN and
7.3 Hz for DZ on Dectin-1-expressing MM6 cells; Figures 1D
and S3A). For competition experiments, we saturated Dectin-1-
expressing MM6 cells with DZ and measured any additional
changes in frequency upon subsequent injections of vesicle-
bound annexin A1DN. Data shown in Figure 1E demonstrate
that vesicle-bound annexin A1DNwas still able to bind toDZ-satu-
rated MM6 cells with kinetics identical to vesicle-bound annexin
A1DN alone (Figures 1D and 1E). Moreover, we obtained similar
results by applying the ligands in reverse order (Figure S3C). In
summary, our data prove that the lipid-bound annexin A1 core
domain binds to a distinct binding site of Dectin-1 not interfering
with the binding of pathogen-derived b-glucans.
The Annexin Core Domain Induces Dectin-1-Dependent
SYK-Phosphorylation and Production of Reactive
Oxygen Species (ROSs)
Oneof theearliest signalingeventsdownstreamofb-glucan-medi-
atedDectin-1 activation is the phosphorylation of SYKbySrc fam-
ily kinases (Reid et al., 2009; Dambuza and Brown, 2015). To test
whether the annexin core domain initiates Dectin-1-dependent
SYK-phosphorylation, we used an antibody recognizing intracel-
lular SYK-phosphorylation on Tyr348. In MM6 and primary bone-
marrow-derived DCs (BMDCs), soluble annexin A1DN induced
Tyr348 SYK-phosphorylation in a Dectin-1-dependent manner
(Figures2A,2B, andS4C). In linewith theeffects of soluble annexin
A1DN, this phosphorylation of SYKwas also observed upon incu-
bation with vesicle-bound annexin A1DN and ACs (Figures S4A
and S4B). Interestingly and in correlation with the unique Dectin-1
binding modality described above, the kinetics of SYK-phosphor-
ylation proved to be different between annexin A1DN and
b-glucans. While DZ induced a long-lasting SYK-phosphorylation
(R30 min), annexin-mediated SYK-phosphorylation was charac-
terized by a short peak after 15 min, which declined quickly tobaseline level (Figure2C;datanot shown). To investigate thediffer-
ences between Dectin-1-mediated b-glucan and annexin
signaling, respectively, we analyzed the phosphorylation status
of SYK in more detail. Our results clearly show that the annexin
core domain as well as soluble, filtered b-glucan (0.45 mm mem-
brane) induces phosphorylation of Tyr348 and Tyr352 within the
SH2/SH3-linker of SYK, which allows for association and activa-
tion of phospholipase C (PLC) isotype g (PLCg) and leads to
inductionofROSs (Lawetal., 1996; Figure2D). Interestingly, phos-
phorylation on Tyr525/526 of the SYK activation loop, required for
NF-kBactivation, remainedunphosphorylateduponannexin incu-
bation (Figure 2D). In contrast, large particulate b-glucans induced
strong phosphorylation of all tyrosines investigated (Tyr348,
Tyr352, and Tyr525/526; Figure 2D).
Dectin-1 engagement and SYK-phosphorylation on Tyr348 and
Tyr352 lead tosubsequentgenerationofROSs (Blanco-Mene´ndez
et al., 2015; Reid et al., 2009; Law et al., 1996). Measuring
cellular ROS levels after stimulation with annexin A1DN using
20,70-dichlorodihydrofluorescein diacetate (H2DCFDA), we de-
tected a time-dependent increase of ROS production peaking
after 2 h (Figure S4D). We confirmed the annexin A1DN-mediated
ROS-induction using the horseradish-peroxidase-based Amplex
Red Assay Kit (Figure S4E). Using BMDCs and MM6 cells, we
were able to demonstrate that annexin-mediated generation of
ROSs clearly is a Dectin-1-dependent effect observed after treat-
mentwith soluble and vesicle-boundannexinA1DNorannexinA5,
respectively (Figures 2E–2G). The specificity of these assays was
further assessed by using heat-inactivated annexin as well as the
specific ROS scavenger Trolox (Figure 2E). Consistently, reconsti-
tution of Dectin-1 expression in Dectin-1 KO MM6 cells could
rescue the annexin-mediatedphenotypewith respect toROSpro-
duction (Figure S4F). Of note, Dectin-1-independent ROS induc-
tion by phorbol 12-myristate 13-acetate (PMA) was unaltered in
all cellular systems. Furthermore, inhibition of SYK-phosphoryla-
tion abrogated the annexin A1DN-mediated ROS increase, indi-
cating that annexin A1DN induces a SYK-dependent ROS signal
(Figure 2H). Taken together, these data show that the annexin A1
core domain and annexin A5 serve as endogenous ligands for
the CLR Dectin-1, leading to selective SYK-phosphorylation on
Tyr348 and Tyr352 and ROS production. In comparison to the
oxidative burst provoked by PMA or pathogen-derived DZ in
BMDCs, annexin treatment inducesmoderate ROS levels, indica-
tive of its role in signaling cascades rather than in b-glucan-
mediated antimicrobial defense (Figure 2G) (Di Meo et al., 2016;
Zhang et al., 2016).
Annexin-Induced ROSs Are NADPH Oxidase-2
Dependent
Within cells, ROSs are generated by different cellular sources
localized in the cytosol, in peroxisomes, at mitochondrial mem-
branes and at the plasma membrane (Di Meo et al., 2016). The
main source of ROSs in DCs and other phagocytes is the
plasma-membrane-bound enzyme complex NADPH oxidase-2
(NOX-2), which catalyzes the formation of the superoxide radical
O2, which is rapidly dismutated into hydrogen peroxide (H2O2)
in the extra-cytosolic environment (Cachat et al., 2015; Di Meo
et al., 2016). In a first attempt to characterize the source of
annexin-induced ROSs, we aimed to scavenge extracellularCell Reports 29, 4435–4446, December 24, 2019 4437
Figure 2. Annexin Induces SYK-Phosphory-
lation and Production of ROSs in a Dectin-1-
Dependent Manner
(A–C) Spleen tyrosine kinase (SYK) phosphoryla-
tion in bone-marrow-derived DCs (BMDCs) (A) or
human MM6 cells (B) was analyzed by flow cy-
tometry. Cells were treated as indicated in the
presence of the phosphatase inhibitor sodium
vanadate (1 mM) (A and B) or without phosphatase
inhibition in WT BMDCs (C) and stained intracel-
lularly by an antibody against phosphorylated SYK
(p-SYK) on Y348. PE-MFI, phycoerythrin median
fluorescence intensity.
(D) Detection of p-SYK on Y348, Y352, and Y525/
526. 5 3 105 Dectin-1-expressing MM6 cells were
starved for 2 h in RPMI/1% FCS/0.1% oxaloace-
tate pyruvate insulin media supplement (OPI) and
treated with indicated ligands in the presence of
the phosphatase inhibitor sodium vanadate (1 mM)
for 20 min. Lysates of 2.5 3 105 cells were loaded
on a SDS gel and analyzed onwestern blot (WB) for
the indicated p-SYK residues. Results are repre-
sentative of three independent experiments.
(E–H) Intracellular ROS levels were deter-
mined by 20,70-dichlorodihydrofluorescein diacetate
(H2DCFDA) in MM6 cells (E and F) and in BMDCs
(G and H). (H) 8 mg/mL DZ and 1,000 nM AnxA1DN
were used. Phorbol 12-myristate 13-acetate (PMA)
and the Dectin-1 ligands DZ and laminarin were
used as positive controls. Co-treatment of annexin
(Anx) A1DN with the ROS scavenger 6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid (Tro-
lox) as well as heat-inactivated (h.i.) AnxA1DN were
used as negative controls. FITC-MFI, fluorescein
isothiocyanate mean fluorescence intensity; PSV,
PS-containing vesicles.
Results in (A)–(C) and (F) represent themean± SDof
one representative experiment out of two or (H) one
representative experiment out of three. In (E) and (G),
the mean ± SD of three (mAnxA5, h.i. mAnxA1DN,
DZ), four (mAnxA1DN + Trolox), eight (mAnxA1DN
[500nM], PMA), or nine (mAnxA1DN [1000nM]) in-
dependent experiments are shown. ****p < 0.0001;
***p<0.001; **p<0.01; *p<0.05; n.s., not significant;
n.d., no FITC-MFI increase detected (unpaired, two-
tailed t test). See also Figure S4.H2O2 by using the membrane-impermeable enzyme catalase.
Addition of catalase to themedium abrogated annexin-mediated
ROS production (Figures 3A and S4G). Thus, we considered
membrane-bound NOX enzymes as likely candidates for the
source of annexin-mediated ROSs. To further clarify the involve-
ment of NOX, we additionally used the nonspecific NOX inhibitor
diphenyleneiodonium (DPI). As observed for catalase treatment,
pretreatment with DPI blocked annexin-induced ROSs (Figures
3B and S4G).
Of all NOX isoforms, Dectin-1 stimulation by b-glucans has
been particularly associated with activation of NOX-2 (Tam
et al., 2014; Blanco-Mene´ndez et al., 2015). For specific target-
ing of NOX-2 in our assays, we used the peptide inhibitor
gp91-TAT that competitively inhibits NOX-2 assembly, but not
the activation of other NOX enzymes (Csa´nyi et al., 2011). In
agreement with a role for NOX-2 in annexin signaling, gp91-
TAT significantly reduced annexin-induced ROS production4438 Cell Reports 29, 4435–4446, December 24, 2019compared to the control peptide Scr-TAT (Figures 3C and
S4H). Consistent with this, the NOX-2-specific small-molecule
inhibitor GSK2795039 also blocked annexin-induced ROSs (Fig-
ure 3D) (Hirano et al., 2015). Finally, we performed ROS experi-
ments in BMDCs deficient for the main subunit of the NOX-2
complex, gp91 (gp91phox(Y/X) male mice), and compared them
with BMDCs from wild-type (WT) littermates. In line with our pre-
vious results, the ROS signal of annexin was dramatically
reduced in NOX-2-deficient BMDCs (Figures 3F and S5A).
However, stimulation by the NOX-independent ROS inducer
rotenone remained unaffected (Figure S5B). Altogether, these
experiments identify NOX-2 as a critical mediator of annexin-
mediated ROS production after binding to Dectin-1.
Intriguingly, not all hallmarks of Dectin-1 signaling following
stimulation by b-glucans were initiated by annexin A1DN. In
contrast to Dectin-1-specific ligands such as DZ, annexin
A1DN did not activate the transcription factor NF-kB or induce
Figure 3. Annexin-Induced ROSs Are
Derived from NADPH Oxidase-2
H2DCFDA ROS detection experiments were per-
formed as described in Figure 2.
(A–D) Dectin-1-expressing BMDCs were pre-
incubated for 30–60 min with the indicated ROS
scavenger before addition of the treatment. Results
representmean ± SD of at least two (B), three (D), or
four (A andC) independent experiments. (E) BMDCs
from NOX-2-deficient mice or WT littermates were
treated with indicated ligands. Quantification of six
independent experiments. The relative ROS-in-
crease is normalized to untreated cells and the
ROS-increase of WT control cells were set to 1 (WT
BMDCs: black circles; NOX-2 KO BMDCs: orange
squares). FITC, fluorescein isothiocyanate; MFI,
mean fluorescence intensity. ***p < 0.001, **p <
0.01, *p < 0.05 (paired, two-tailed t test). Significant
outliers (r values < 0.05) as determined by
GraphPad outlier calculator were removed.
See also Figure S5.inflammatory cytokine secretion (Figures 4A–4D). As described
by Goodridge et al. (2011), extensive receptor clustering or
formation of a synapse is required for activation of NF-kB and
induction of cytokine secretion, respectively. In order to investi-
gate Dectin-1 binding in the absence of extensive receptor clus-
tering, we abrogated the ability of DZ to form large receptor/
ligand clusters by filtering (0.45 mm). Indeed, such filtered, solu-
ble DZ retained its ability to bind to Dectin-1 and induce ROS
production, whereas we could not observe any activation of
NF-kB or secretion of inflammatory cytokines (Figures 4E, 4F,
and S3A; data not shown). These results imply that binding to
Dectin-1 by ligands that do not induce extensive receptor clus-
tering, such as the annexin core domain or soluble, filtered DZ,
induce only selective Dectin-1 signaling events.Dectin-1 Mediates Immunosuppressive Effects of ACs
and Annexins
Externalization of annexins on ACs is critically involved in the in-
duction of a tolerogenic DC-phenotype and the development of
peripheral tolerance (Weyd, 2016). This immunosuppressive effect
of ACs or annexins on DCs is illustrated by reduced responsive-
ness to Toll-like receptor (TLR) stimulation (Voll et al., 1997;
Weyd et al., 2013). In the following experiments, we tested theCell Reportrole of Dectin-1 in immunosuppressive
effects of ACs or the annexin core domain,
respectively.Asdescribedbefore,ACsand
annexin A1DN exerted a strong immuno-
suppressive effect on Dectin-1-expressing
cells demonstrated by almost complete
reduction (percentage of stimulation) of
TLR-induced pro-inflammatory cytokine
secretion (Weyd et al., 2013; Linke et al.,
2015). In contrast, Dectin-1 KO cells were
significantly less inhibited by both annexin
A1DN and human as well as murine ACs
(Figures 5A–5F and S6). Moreover, sup-
pression of the co-stimulatory DC surfacemarker CD80 was prevented in Dectin-1 KO cells (Figures 5G
and 5H). It is worth noting that the suppressive capacity of annexin
A1DN was reduced in Dectin-1-deficient cells compared to WT
cells in all corresponding experiments. Altogether, these data
outline an important role for Dectin-1 as immunosuppressive
receptor in response to ACs and the annexin A1 core domain.
Effective Immunosuppression by ACs and Annexins
Requires ROSs
As shown above, annexin-mediatedROSproduction is abrogated
by pretreatment with NOX-2-specific inhibitors or in NOX-2-defi-
cient BMDCs, confirming that NOX-2 is the main ROS-producing
enzyme after annexin incubation. Next to its well-known role in
antimicrobial defense, NOX-2 has also described to be involved
in anti-inflammatory processes as well as in prevention of autoim-
mune diseases (Olofsson et al., 2003; Rosenzweig, 2008; Lee
et al., 2011; Holmdahl et al., 2013; Kelkka et al., 2014; Segal
et al., 2010). Thus, we investigated whether annexin- and AC-
induced immunosuppression was dependent on the induction
of ROSs. Indeed, the H2O2-scavenger catalase reduced the
suppressive effects of ACs and annexin compared to control-
treated cells (Figures S7A–S7C). Accordingly, the suppressive
effects of ACs and annexins were strongly reduced in functionals 29, 4435–4446, December 24, 2019 4439
Figure 4. ACs, Recombinant AnxA1DN, and
Filtered DZ Do Not Activate NF-kB
(A) Dectin-1 expressing NF-kB reporter cells (see
STAR Methods) were treated with indicated li-
gands overnight. After 16h and 24h, activity of
secreted embryonic alkaline phosphatase (SEAP)
was assessed in the supernatant. Results indicate
the mean ± SD of one representative experiment
out of two.
(B) Dectin-1-deficient and WT BMDCs were incu-
bated with indicated Dectin-1 agonists overnight.
Cytokine concentrations in the supernatants were
analyzed by ELISA 20-24 h after stimulation.
(C and D) WT BMDCs were stimulated with indi-
cated treatment overnight. Cytokine concentra-
tions in the supernatants were analyzed by ELISA
24 h after stimulation.
(E) Dectin-1-expressing NF-kB reporter cells were
treated with indicated ligands overnight as
described in (A).
(F) Intracellular ROS levelswere determinedby20,70-
dichlorodihydrofluorescein diacetate (H2DCFDA) in
WT BMDCs as described in Figure 2. Results
represent the mean ± SD of one out of two inde-
pendent experiments.experiments using GSK2795039 (Figures 6A–6C and S7D–S7I)
and gp91-TAT (Figures 6D–6G and S7J–S7Q) for inhibition of
NOX-2. Finally, we confirmed the functional relationship between
NOX-2-dependent ROS production and immunosuppression us-
ing gp91phox(Y/X) BMDCs (Figures 6H–6KandS7R–S7U).Wealso
observed significantly enhanced secretion of pro-inflammatory
cytokines such as interleukin-6 (IL-6) and IL-12 in gp91phox (Y/X)
BMDCs after stimulation with a Dectin-1-specific b-glucan,
confirming the inhibitory function of NOX-2-derived ROSs in
Dectin-1-activated cells as described before (Figures S5C and
S5D) (Scha¨ppi et al., 2008; Segal et al., 2010).
Our data clearly show the relevance of NOX-2-induced ROSs
for Dectin-1-mediated immunosuppression in response to the an-
nexin core domain and ACs. Furthermore, the molecular mecha-
nism of AC-mediated immunosuppression we have described
here provides a rationale for the role of NOX-2 in regulating hy-
per-inflammatory immune responses and autoimmune diseases.
Dectin-1 KO Mice Show Age-Related Symptoms of
Autoimmunity and Enhanced Immune Responses
against AC-Derived Antigens
The in vitro results presented abovedelineate an immunoregulatory
molecular pathway initiated by AC-bound annexin, which activates
Dectin-1 and leads to DC-inhibition via phosphorylation of SYK fol-
lowedbyNOX-2-dependentROS release.Weanticipated that defi-
ciency in either of these components would likely result in an auto-4440 Cell Reports 29, 4435–4446, December 24, 2019immune phenotype. Regarding NOX-2, it is
well documented that mutations in mem-
bers of the NOX-2 complex are responsible
for a diverse set of autoimmune disorders,
including rheumatoid arthritis or lupus
erythematosus (Olofssonetal., 2003;Rose-
nzweig, 2008; Segal et al., 2010). However,Dectin-1-deficient mice have not been described to develop an
overt autoimmune phenotype so far. We reasoned that autoim-
mune symptoms related to loss of Dectin-1 might accumulate
with age as observed for other immune-regulators such as pro-
grammed cell death protein 1 (Nishimura et al., 1999) and thus
investigated immune parameters in agedmice (77 weeks). We ex-
pected signs of hyper-inflammation in Dectin-1 KO mice due to a
lack of sufficient DC and macrophage suppression during homeo-
static turnover of engulfed ACs. Indeed, aged Dectin-1 KO mice
showed severely enlarged spleens compared to WT littermates
(Figure 7A). Moreover, DCs and macrophages in spleens of aged
Dectin-1 KO mice displayed an activated phenotype as analyzed
by CD80 or CD86 (co-)expression (Figures 7B–7E). Importantly,
the activated cellular phenotype in aged Dectin-1 KO mice was
accompanied by a higher titer of autoantibodies (immunoglobulin
M [IgM] and IgG isotypes) targeting double-stranded DNA (Figures
7F–7H). In order to investigate the role of AC-mediated immune
regulation in Dectin-1-deficient mice, we injected ACs stably ex-
pressingmurine annexin A1 (mAnxA1) and themodel antigen oval-
bumin (OVA) intoWT andDectin-1 KOmice (Figure 7I). As depicted
in Figure 7J, we observed a significant increase in OVA-specific
CD8+ T cells in draining lymph nodes of Dectin-1 KO mice
compared to WT littermates. This observation indicates that Dec-
tin-1-deficient mice lack immunosuppressive signaling when
encountering ACs and thus mount stronger immune responses
against AC-derived antigens (Figure 7J). In contrast to WT
Figure 5. Dectin-1 Mediates Immunosup-
pressive Effects of ACs and Annexins
BMDCs were incubated with mouse (m) annexin
(Anx) A1DN (1,000 nM), apoptotic Jurkat T cells (aJ;
ratio of 0.5:1 or 0.1:1) or apoptotic RMAcells (aRMA;
ratio of 4:1) for 8 h. After preincubation, BMDCs
were stimulated over night with the TLR agonist
CpG. Cytokine concentrations in the supernatants
were analyzed by ELISA 16–24 h after stimulation
(see representative experiments depicted as actual
cytokine secretion in Figures S5A–S5P).
(A–F) Quantification of indicated independent ex-
periments (n = 4–6). The cytokine secretion is
normalized to CpG-stimulation minus background
(100  ((treated - untreated)/(CpG only  un-
treated)) 3 100). The range of cytokine secretion
was (A) 154–2,039 pg/mL, (B) 609–22,879 pg/mL,
(C) 62–4,425 pg/mL, (D) 1,796–9,487 pg/mL, (E)
960–7,273 pg/mL, and (F) 7,513–19,413 pg/mL.
(G and H) CD80 surface staining was analyzed by
flow cytometry after preincubation with eukaryoti-
cally expressed mAnxA1DN following simulation
with CpG for 2–3 days.
(G) Representative histogram of CD80 expression
in WT (left) and Dectin-1 KO BMDCs (right) with
indicated treatments.
(H) Quantification of CD80 surface marker
expression. Results represent the mean ± SEM
of five independent experiments. ***p < 0.001;
**p < 0.01; *p < 0.05 (paired, two-tailed t test).
See also Figure S6.littermates, levels of the inflammatory biomarker soluble urokinase
receptor (uPAR) as well anti-AC antibodies were also elevated in
AC-injected Dectin-1-deficient mice (Figures 7K and 7L). Taken
together, the autoimmune symptoms prevalent in aged Dectin-1
KOmice as well as stronger immune responses to AC-derived an-
tigens inDectin-1KOmicedemonstrate an involvement ofDectin-1
in homeostatic immune-regulation. Furthermore, this autoimmune
phenotype in vivosupportedbyour in vitrostudies revealsan impor-
tant role for Dectin-1 in AC-mediated immunosuppression and in
turn preventing the development of immune hyper-activation and
autoimmunity.
DISCUSSION
Data presented in this study identify the CLRDectin-1 as an immu-
nosuppressive signaling receptor for annexins exposed on the sur-
face of ACs. The fact that Dectin-1 and other CLRs bind endoge-
nous ligands in addition to pathogen-derived ligands has been
described before. Dectin-1 recognizes carbohydrate alterations
aswell as protein ligands, but the binding sites of endogenous pro-
tein ligands have not been investigated (Weck et al., 2008; Sancho
andReis e Sousa, 2013; Thiagarajan et al., 2013; Daley et al., 2017;
Brown et al., 2018). Here, we show that the recognition site of theCell Reportannexin core domain on Dectin-1 is distinct
from its b-glucan-binding site. We deter-
mined a nanomolar affinity range of
several annexin family members binding
to Dectin-1, which compares well to the af-finity of the inhibitory Dectin-1 ligand laminarin (Adams et al., 2008).
UsingQCM technology,we calculated an affinity for the soluble an-
nexin A1 core domain and annexin A5 to Dectin-1-expressing cells
of408nMor7.1nM, respectively (TableS1). Thisbindingaffinity
was substantially increased when vesicle-bound annexin A1 core
domain was applied to Dectin-1-expressing cells (data not shown).
Because the annexin core domain is bound to PS on the surface of
ACs under physiological conditions, this observation indicates a
supportive role for PS binding that results in enhanced annexin
A1/Dectin-1 interaction.
In line with the unique binding site mentioned above and in
contrast to Dectin-1-dependent phagocytosis of b-glucans
(Dambuza and Brown, 2015), we could not detect a prominent
role for the Dectin-1/annexin interaction in phagocytosis or ef-
ferocytosis in BMDCs (data not shown), likely due to additional
phagocytic receptors on BMDCs. A plethora of receptors has
been described to be involved in the uptake of ACs (Arandje-
lovic and Ravichandran, 2015). In addition to PS receptors
such as TREM-2, TIM-4, and CD300, lectin receptors binding
to altered sugar residues presented on ACs or CD14 binding
to AC-specific ICAM-3 may also be responsible for uptake of
ACs in a highly redundant manner. According to our data,
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Figure 6. Effective Immunosuppression of
AC-Derived Annexins Requires ROSs
(A–G) Quantification of suppression experiments
performed as in Figure 5 for indicated cytokines.
WT BMDCs were preincubated with NOX-2 in-
hibitors GSK2795039 (A–C) or gp91-TAT (D–G) for
30 min. Subsequently, apoptotic Jurkat T cells
(aJ; ratio of 0.5:1) (C, F, and G) or eukaryotically
expressed mAnxA1DN cells (1,000 nM) (A, B, D,
and E) were added, and BMDCs were further
incubated for 8 h.
(H–K) BMDCs generated from NOX-2-deficient
mice and WT littermate controls were incubated
with aJ cells (ratio of 2:1) (J and K) or mAnxA1DN
(500 nM) (H and I). After preincubation, BMDCs
were stimulated with the TLR agonist CpG. Indi-
cated cytokines in the supernatants were analyzed
by ELISA 20-24 h after stimulation.
The rangeofcytokine secretionwas75–3,746pg/mL
(A), 270–10,798 pg/mL (B), 745–4,298 pg/mL (C),
1,017–3,111pg/mL (D), 4,197–6,832 pg/mL (E), 384–
2,543 pg/mL (F), 2,153–8,465 pg/mL (G), 93–1,159
pg/mL (H), 438–3,540 pg/mL (I), 1,702–3,318 pg/mL
(J), and2,885–5,766pg/mL (K).Results represent the
means of three (F–K), four (D and E), or seven (A–C)
independent experiments. ***p < 0.001; **p < 0.01;
*p < 0.05 (paired, two-tailed t test).
See also Figure S7.appears to be mediated mainly by phagocytic receptors other
than Dectin-1.
Our results clearly show that the annexin A1 core domain and
soluble, filtered b-glucans induce SYK-phosphorylation of
Y348 and Y352 (Figure 2D). These residues are located within
the SH2/SH3-linker of SYK required for binding and activation
of PLCg and ROS induction. Interestingly, Y525/526 within
the SYK activation loop and important for NF-kB activation
(Law et al., 1996) remained unphosphorylated (Figure 2D). In
contrast, large particulate b-glucans induced prominent phos-
phorylation of all tyrosines investigated (Figure 2 D). Based on
these results, we conclude that the annexin A1 core domain in-
duces a distinct, non-canonical activation of Dectin-1 that is not
dependent on extensive receptor clustering described for
particulate b-glucans (Plato et al., 2013). Further observations
support this conclusion. Soluble, filtered DZ mimics binding4442 Cell Reports 29, 4435–4446, December 24, 2019of the annexin A1 core domain to
Dectin-1 and loses its ability to activate
NF-kB or induce cytokine secretion,
respectively (Figure 4E; data not shown),
while selective SYK-phosphorylation
and induction of ROS production is pre-
served (Figures 2D, S3A, and 4F).
Thus, the annexin A1 core domain
selectively engages an anti-inflammatory
branch of the Dectin-1 signaling pathway
(Scha¨ppi et al., 2008; Trinath et al., 2014).
Such functional selectivity, also known as
‘‘biased agonism,’’ has been described
for other ligand/receptor systems (Smith
et al., 2018). Selective activation ofDectin-1 by the annexin core domain induces a tolerogenic DC
phenotype after phagocytosis of ACs and thus ensures the
maintenance of peripheral immune tolerance.
Recognition of the annexin core domain by Dectin-1 leads to
SYK-mediated induction of NOX-2-dependent release of ROSs
that are known signaling events of many other Dectin-1 ligands
(Tam et al., 2014; Blanco-Mene´ndez et al., 2015; Dambuza and
Brown, 2015). However, annexin-induced intracellular ROS
levels were substantially lower than the ROS levels characteristic
of an oxidative burst, indicative of a role in signaling cascades
(Zhang et al., 2016). The inhibitory function of NOX-2-derived
ROSs is supported by publications describing NOX-2-derived
ROSs as a factor in limiting hyper-inflammatory Dectin-1 re-
sponses (Scha¨ppi et al., 2008; Segal et al., 2010). Moreover, it
is known that NOX-2-derived ROSs play a substantial role in
the prevention of autoimmune diseases in mice, rats, and
(legend on next page)
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humans (Olofsson et al., 2003; Rosenzweig, 2008; Lee et al.,
2011; Holmdahl et al., 2013; Kelkka et al., 2014; Segal et al.,
2010).
The inhibitory role of the annexin/Dectin-1 axis was sup-
ported by data when testing immune responses against
AC-derived antigens in vivo. Here, we observed an increase
in AC-specific CD8+ T cells in Dectin-1 KO mice compared to
WT littermates accompanied by higher levels of uPAR and
elevated anti-AC-specific antibodies in sera of AC-injected
Dectin-1-deficient mice (Figure 7). The lack of inhibitory
signaling in response to ACs apparent in Dectin-1-deficient
mice also became evident in aged Dectin-1 KO mice. In fact,
spleens of old Dectin-1 KO mice were enlarged and showed
up to a 2-fold increase in weight. Moreover, an activated im-
mune phenotype in aged Dectin-1 KO mice became evident
by upregulation of activation markers on splenic DCs and mac-
rophages. Importantly, these signs of immune activation in
aged Dectin-1 KO mice were accompanied by elevated titers
of anti-dsDNA autoantibodies. While Dectin-1-sufficient mice
developed only IgM anti-dsDNA antibodies, in aged Dectin-1
KO mice, we observed an isotype switch toward anti-dsDNA
IgG antibodies, which are known to closely correlate with dis-
ease onset and severity of autoimmune disorders such as
systemic lupus erythematosus in humans (Fo¨rger et al., 2004).
Our findings are supported by other studies that describe
the induction of anti-inflammatory and tolerogenic responses
upon Dectin-1 activation by b-glucans (Dillon et al., 2006; Kar-
umuthil-Melethil et al., 2014, 2015).
We identified an essential role for NOX-2-derived ROSs in AC-
and annexin-mediated DC-inhibition. In agreement with these
findings, NOX-2-deficient mice develop an autoimmune pheno-
type with an onset at 5 weeks after birth that is characterized by
arthritis- as well as lupus-like symptoms (Cachat et al., 2015; Lee
et al., 2011). The pathologies in NOX-2-deficient mice appear
to be more severe than the symptoms we observed in aged
Dectin-1 KO mice. This difference is probably explained by the
fact that AC- and annexin-mediated DC-inhibition was not
completely abrogated in Dectin-1 KO BMDCs, suggesting that
additional receptors known to signal via NOX-2 may contribute
to this inhibitory mechanism. Nevertheless, we assume that
Dectin-1 deficiency may result in a more severe autoimmuneFigure 7. Dectin-1 KO Mice Exhibit Symptoms of Autoimmunity and G
(A) Spleen weight of aged WT and Dectin-1 KO mice.
(B–E) Splenocytes only (B) or DCs (CD11c+ and major histocompatibility complex
(D and E) of isolated splenocytes were stained in combination with the activati
macrophagemarker CD206 (E) and analyzed by flow cytometry. Results represen
n.s., not significant (unpaired, two-tailed t test).
(F–H) Blood plasma of aged mice obtained from cardiocentesis were collected an
by ELISA. Results represent the median of five to eight mice per group. **p < 0.0
(I–L) Dectin-1 KOmice andWT littermates were injected with apoptotic S2 cells (aS
aS2-mAnxA1/OVA cells) on days 0 and 7.
(I) Schematic representation of the experiment.
(J) OVA-specific CD8+ T cells of the draining lymph node (dLN) were stained with
(K) The serum level of soluble urokinase receptor (uPAR) was measured 1 day
injection (d3), and 7 days after the second injection of aS2-mAnxA1/OVA cells (d
(L) Serum of WT and Dectin-1-deficient mice obtained from indicated time points
Results represent the mean ± SD (J) and (K) or mean ± SEM (L) of 5 mice per gro
dashed line in (F)–(H) represents the absorbance of the negative control casein o
fluorescence intensity.
4444 Cell Reports 29, 4435–4446, December 24, 2019phenotype upon environmental challenges of the immune sys-
tem (Cusick et al., 2012; Gour et al., 2018).
The molecular pathway of AC-derived annexin, stimulating
Dectin-1 and inducing cellular inhibition of DCs via NOX-2-
derived ROSs, represents an important mechanism of peripheral
immune tolerance. Therapeutic manipulation of the annexin/
Dectin-1/NOX-2 checkpoint system such as coupling autoanti-
gens to the annexin A1 core domain may provide future strate-
gies for treatment of autoimmune diseases.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND CODE AVAILABILITYrate Enhanced Immune Responses to ACs
s II [MHC class II]+) (C) and macrophages (MV, F4/80+, and MHC class II+)
arkers CD80 and CD86 (C and D) as well as the anti-inflammatory M2-
mean ± SD of five to eight mice per group. ***p < 0.01; **p < 0.01; *p < 0.05;
alyzed for indicated autoantibodies against double-stranded DNA (dsDNA)
p < 0.05 (Mann-Whitney test).
ells) stably expressingmAnxA1 andmembrane-anchored ovalbumin (OVA;
NFEKL dextramers.
re the first injection (preimmunization [pre immun.]), 3 days after the first
incubated with S2-mAnxA1/OVA cells and stained with PE-labeled a-mIg.
**p < 0.01; *p < 0.05; n.s., not significant (unpaired, two-tailed t test). The
WT: black circles; Dectin-1 KO: red squares. BW, body weight; MFI, mean
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter H.
Krammer (p.krammer@dkfz-heidelberg.de) with a completed Materials Transfer Agreement. We are glad to share all reagents with
compensation by requestor for shipping. Stocks from recombinant annexins may need to be re-produced. Bone marrow (BM) of
gp91phox (Y/X-) KO (B6.129S-Cybbtm1Din/J) and gp91phox (Y/X+) WT male mice was kindly provided by V. Jaquet (University of Geneva,
Geneva, Switzerland). The pCas9_GFP plasmid was a gift from Kiran Musunuru (Addgene plasmid # 44719). The OVA-expressing
RMA cell line was a gift from G. Ha¨mmerling (DKFZ, Heidelberg, Germany).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Male and female mice of Dectin-1(/) KO (B6.129S6-Clec7atm1Gdb/J) and Dectin-1 wild-type (WT; C57BL/6J) littermates were main-
tained and bred under specific pathogen-free conditions at the animal facility of the German Cancer Research Center, Heidelberg. All
animal studies were approved by the veterinary authorities (Regierungspra¨sidium Karlsruhe) of Baden-W€urttemberg (DKFZ346 and
G291-14). NOX-2 KOmice were generated by M. C. Dinauer and are available from JAX (https://www.jax.org/strain/002365; Pollock
et al., 1995). Littermates of gp91phox (Y/X-) KO (B6.129S-Cybbtm1Din/J) and gp91phox (Y/X+) WTmalemice were bred using heterozygous
gp91phox (X+/X-) female and hemizygous gp91phox (Y/X-) KO male mice. The mice were bred under standard conditions at the animal
facility of theCentreMe´dical Universitaire of the Faculty of Medicine, University of Geneva. No obvious problems regarding infections
were observed in these mice.
Cell Lines
The human T cell line Jurkat E6.1 (Schneider et al., 1977) was cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% FCS.
Murine RMA cells stably expressing OVA in the cytoplasm (Tiwari et al., 2007) were cultured using RPMI 1640 supplemented with
10% FCS, 50 mM 2-Mercaptoethanol (Sigma-Aldrich) and 100 mg/ml Geneticin sulfate (G418; GERBU Biotechnik). Human Mono
Mac 6 (MM6; Ziegler-Heitbrock et al., 1988) cells were cultured in RPMI 1640, 10% FCS and 1% OPI-supplement (SIGMA-Aldrich).
Drosophila melanogaster S2 cells (S2-cells) stably expressing murine Annexin A1 (mAnxA1) and membrane-anchored OVA
(S2-mAnxA1/OVA cells) were generated previously (Linke et al., 2015). S2-mAnxA1/OVA cells were cultured in Schneider’s
insect medium (Sigma-Aldrich) supplemented with 10% FCS and Hygromycin B (PAA). The human hDectin-1b-expressing
HEK293 NF-kB reporter cell-system was obtained from Invivogen and cultured according to the manufacturer’s instructions.
METHOD DETAILS
Preparation of Bone-Marrow–Derived Dendritic Cells
Bone marrow (BM)-derived dendritic cells (DCs, BMDCs) were prepared frommale or female mice between 6 and 14 weeks (wks) of
age, as described before (Linke et al., 2015). In brief: BM cells were flushed from tibias and femurs, and red blood cells were lysed by
brief exposure to 0.168 M NH4Cl and further washed twice with RPMI 1640 (Sigma-Aldrich) supplemented with 10% FCS (Sigma-
Aldrich). For differentiation of BM precursors to BMDCs using recombinant murine GM-CSF (Immunotools), cells were seeded at
a density of 0.5x106 cells/ml in BMDC medium (RPMI 1640 with 10% FCS and 20 ng/ml GM-CSF) in a 24-well plate. After 2 d,
the medium was carefully replaced by fresh BMDCmedium (37C). After 5 d, half of the medium was removed and replaced by fresh
BMDCs medium (37C). Experiments were conducted on d 6 of differentiation. The differentiation of BM precursors to BMDCs was
monitored by flow cytometric analysis using monoclonal antibodies (mAbs) against CD11b, CD11c, CD80, CD86, PD-L1, DEC-205,
MHC class II and Dectin-1 (listed in Key Resources; data not shown).
Flow Cytometry
All staining procedures were performed in PBS/10%FCS/10%mouse or rat serum. Abs and reagents used for FACS were purchased
from BioLegend (anti-mCD86-APC-Cy7, anti-mCD11c-APC, anti-mMHC class II-PerCP-Cy5.5, anti-mF4/80-APC-Cy7, anti-mCD80-
FITC, anti-mPD-L1–PE, anti-mDEC-205-PE-Cy7), eBioscience (anti-p-SYK (Tyr348)PE, anti-hDectin-1-PE), Caltag (anti-mCD11b-
PE), BD Biosciences (anti-mCD80-PE), LIFE Technologies (anti-hSYK-APC) and Abcam (anti-mDectin-1-FITC). Appropriate isotype
controls were purchased from Biolegend or eBioscience. Phosphatidylserine exposure and cellular membrane integrity were analyzed
by staining with annexin A5 (AnxA5)-FITC (Immunotools) or AnxA5-APC (Immunotools) and 7-aminoactinomycin D (7-AAD; Sigma-
Aldrich), respectively (data not shown). Stained cells were analyzed on a FACS Canto II (BD Biosciences) with FlowJo software
(BD Biosciences).
Antibodies, ELISA, and Reagents
Anti-human (h) annexin A1 (AnxA1) (DAC5) and Anti-mouse AnxA1 (mAx550) Abs were generated in our laboratory (Weyd et al. 2013).
Intracellular p/total-SYK staining’s were performed with or without the phosphatase inhibitor sodium vanadate (Sigma-Aldrich; 1mM)
as indicated, and by permeabilization with Methanol (100%) for 10min by 4C. Cytokine concentrations in supernatants wereCell Reports 29, 4435–4446.e1–e9, December 24, 2019 e5
determined by ELISA for mIL-12p40 (PeproTech), m/hIL-6, hTNFa (both BD Biosciences), according to the manufacturers’ instruc-
tions. Western Blot (WB) detection of human p-SYK was performed using following antibodies against: p-SYK (Tyr525/526; Cell
Signaling Technology), p-SYK (Tyr348; Abcam), p-SYK (Tyr352; Cell Signaling Technology) and total SYK (Cell Signaling Technol-
ogy). Auto-Abs against double-stranded (ds) DNAwere determined by ELISA developed in our laboratory as follows: 10mg/ml dsDNA
(from calf thymus, SIGMA) was captured in coating buffer (0.2 M sodium phosphate buffer, pH 6.5) overnight on 96-well plates
(round-button, LIFE Technologies) at 4C. After blocking for 1 h in 1% Casein (in PBS) on RT, mouse blood plasma samples (1/50
in PBS/10% FCS) were added for 2h. The binding of anti-dsDNA Abs was detected by horseradish peroxidase-conjugated Ig
(isotype)-specific anti-m Abs (goat anti-mIgM, m chain specific, Jackson ImmunoResearch Labs; goat anti-mIgG1, SouthernBiotech;
goat anti-mIgG2b, SouthernBiotech; goat anti-mIgG3, SouthernBiotech; goat anti-mIgG2c, Abcam; anti-mIg, Thermo Fisher
Scientific) using the substrate o-Phenylenediamine (Thermo Fisher Scientific) and the absorbance of 490nm was measured. Lami-
narin, dispersible whole glucan particle (dWGP), depleted zymosan (DZ) and b-glucan peptide (BGP) were purchased from
Invivogen. DZ (1mg/ml) was filtered usingmembranes with different pore sizes (0.2 mm; 0.45 mm; 35 mm) to obtain the soluble fraction
of b-glucans. The concentration of filtered DZ was not determinable but the majority of DZ is present as large particles. Bovine ex-
tracted catalase was purchased from Carl Roth. 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was obtained
from Th. Geyer. SYK inhibition experiments were performed using SYK-inhibitor-2 (200nM). Specific NADPH-oxidase 2 (NOX-2) in-
hibition experiments were performed using the peptide inhibitor gp91 ds-TAT aside with appropriate control scrambled gp91 ds-TAT
(Anaspec), and the small molecule inhibitor GSK2795039 diluted in DMSO (MedChemExpress). Splenic DCs andmacrophages were
isolated using collagenase Typ IV (Biochrome) and DNase I (Roche).
Transfections and CRISPR/Cas9-Mediated Genome-Editing
The plasmid for hDectin-1b (Invivogen) was transfected using AMAXA Cell Line Nucleofector Kit V (Lonza). To generate stably trans-
fected MM6, cells were selected using Blasticidin S Hydrochloride (Thermo Fisher Scientific) for 21 to 28 d or, if necessary, were
separated via FACS using a fluorescently labeled anti-Dectin-1 Ab after 3 to 14 d of Blasticidin selection. Dectin-1-deficient
MM6 cells were generated using CRISPR/Cas9 genome-editing technology as described previously (Ran et al., 2013). In brief:
Dectin-1-specific guide (g)RNAs (gRNA1: 50-AACTTGTTTCACGCTATATC; gRNA2: 50-AAGATGTGCTTCGAGATGTG) targeting
Exon 1 were cloned into the pSpCas9(BB)-2A-GFP Vector (Addgene) that encodes Cas9 linked with a 2A spacer to GFP.
Dectin-1-specific Cas9-GFP vectors were transfected into MM6 cells using AMAXA-Nucleofection technology. After 24 to 48 h,
GFP-positive cells were isolated by FACS. After incubation for 5-7 d, cells were clonally separated in 96-well plates by limiting dilution
(0.1 cells / well) using RPMI 1640 with 10% FCS, 1%OPI-supplement and 10 U/ml penicillin/streptomycin (Sigma-Aldrich). After 2-4
wks, DNA from expanded clones was isolated and the Dectin-1 targeted locus was amplified by PCR. After PCR purification the
Dectin-1 target locus was analyzed by Sanger sequencing (listed in Key Resources Table). Homozygous Dectin-1 nonsense
mutations were confirmed by Sanger-sequencing. Loss of Dectin-1 expression was verified by flow cytometry using Dectin-1
specific mAb and by qPCR. MM6 Dectin-1 KO clones 1 and 2 were generated in two independent experiments.
Generation and Purification of Recombinant Proteins
Plasmids for murine (m)AnxA1DN, mAnxA1, mAnxA5 and human (h)AnxA1DN were generated and purified as described previously
(Linke et al., 2015). For transformation, 100 mL of competent E. coli bacteria were incubated on ice for 30min with 10 ng plasmid DNA.
After a 30 s heat pulse at 42C the suspension was incubated on ice for 2 min and subsequently regenerated for 1 h at 37C in 450 ml
SOC-medium (New England Biolabs). Finally, the bacteria were streaked on LB-agar plates with suitable selectionmedium. Bacterial
colonies grew overnight at 37C. Recombinant annexins were expressed and purified in our laboratory as previously described (Linke
et al., 2015) using the E. coli strain Rosetta (DE3; Novagen). In brief: Expression for 20 h at 18C after induction with 1 mM Isopropyl
b- d-1-thiogalactopyranoside (IPTG; Carl Roth) yielded highest solubility of recombinant annexins. To increase protein production,
bacterial cultivation was conducted in baffled conical flasks. Bacteria were lysed in the presence of Benzonase (Roche) through
successive freeze and thaw cycles in liquid nitrogen and a 38C water bath, respectively. Soluble annexins were purified after
bacterial lysis via its C-terminal Protein A-tag that binds to immunoglobulin G (IgG)-coated beads. Reduction of lipopolysaccharides
(LPS) contamination was achieved by washing with TBS buffer containing 0.1% Triton X-114 (SIGMA-Aldrich). PreScission protease
(GE Healthcare) was used to cleave recombinant annexin from its purification tag. Glutathione beads (GE Healthcare) then served to
remove the glutathione-S-transferase (GST)-tagged protease. Finally, the recombinant protein was cleared from LPS by ion-
exchange purification. The mAnxA1 core domain (mAnxA1DN) was also expressed in eukaryotic Spodoptera frugiperda Sf9 insect
cells using baculovirus. The virus DNA was generated using the Bac-to-Bac Baculovirus Expression System (Invitrogen) in com-
bination with the pFastBac-M30a vector encoding for mAnxA1DN. Following lysis of the cells in the presence of Benzonase and com-
plete protease inhibitor (Roche), insoluble debris was removed via centrifugation for 30 min at 40,000 rpm. Soluble GST-tagged
mAnxA1DN was purified from lysate using a 5 mL Protino GST/4B column (GE Healthcare). After washing, mAnxA1DN was cleaved
from the column using GST-tagged 3C protease. Finally, mAnxA1DN was dialyzed into sodium phosphate based low salt buffer and
freed from LPS through anion exchange chromatography. The production and purification of eukaryotic mAnxA1DN was
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(Stolt-Bergner et al., 2018). LPS content in all annexin preparations was determined to be below 0.001 EU/mg using the Limulus
amoebocyte lysate assay (Lonza) according to the manufacturer’s instructions. If not stated otherwise, procaryotically produced
Anx was used.
Preparation of Apoptotic Cells (ACs)
For induction of apoptosis, 1x106 cells/ml in a total volume of 2.5 ml/well (in 6-well cell culture-treated plates) were irradiated with
75 mJ/cm2 (Jurkat T cells), 500 mJ/cm2 (RMA-OVA cells) or 1000 mJ/cm2 (S2-mAnxA1/OVA UV-C in a Stratalinker 1800 (Strata-
gene/Agilent Technologies) and used after 2–2.5 h (Jurkat T cells and RMA-OVA cells) or 16-20h (S2-mAnxA1/OVA) of incubation
in RPMI/10% FCS at 37C as previously described (Linke et al., 2015). During apoptosis, cytosolic annexins are externalized to
the cell surface of apoptotic cells. About 2 h (Jurkat T cells and RMA-OVA cells) or about 16 h (S2-mAnxA1/OVA) after UV-irradiation
membrane (PS)-bound AnxA1, AnxA5 and AnxA13 can be detected such as by flow cytometry using fluorescently labeled anti-Anx
mAbs (see Key Resources Table; Linke et al., 2015; Weyd et al., 2013; and data not shown).
In Vitro Suppression-Assay with ACs or Recombinant Proteins
A total of 1x105 BMDCs or MM6 cells were incubated with recombinant protein (100-1000 nM), DZ, apoptotic Jurkat T cells
(0.1-4x105 cells) or apoptotic RMA cells (4x105 cells) in the presence of the LPS neutralizing agent Polymyxin B (PmxB; 50mg/ml final
concentration) for 4-8 h. Cells were subsequently stimulated with 10-60 nM CpG 1668 (Invivogen; BMDCs) or 0,5-1 mg/ml R848
(Invivogen; MM6 cells). Cytokine concentrations in the supernatants were analyzed by ELISA 16-24 h after TLR stimulation. CD80
surface expression was measured 2-3 d after TLR stimulation. If not stated otherwise: The suppression of cytokine secretion was
normalized to CpG-stimulation minus background (100 - ((treated - untreated) / (CpG only - untreated)) *100).
RNA Isolation and Quantitative RT-PCR
RNAwas isolated from cells using the RNeasyMaxi Kit (QIAGEN) or RNAqueous-Micro Kit (Ambion), according to themanufacturers’
instructions. Reverse transcribed RNAwas quantified by detection of SYBRGreen (Sigma-Aldrich) incorporation using the ABI Prism
7500 sequence detector system (Applied Biosystems). Expression levels were normalized to mHMBS or hHPRT1.
Detection of Reactive Oxygen Species (ROSs)
Intracellular amounts of ROSs in BMDCs, MM6 and Jurkat T cells were determined using ROS sensitive H2DCFDA (Sigma-Aldrich).
For this, 1x105 cells/well were seeded in RPMI/10% FCS, supplemented with 50 mg/ml of PmxB (Sigma-Aldrich) to exclude LPS-
mediated effects. Treatments such as PMAor annexins were added 1 h later and cells were incubated for 0 to 2.5 h at 37C. Following
treatment, 5 mM of H2DCFDA was added for 0.5 h. The reaction was stopped by addition of 25 mM of the hydroxyl radical scavenger
Trolox or 20mM of the antioxidant N-acetyl-L-cysteine (NAC; Sigma-Aldrich) for 10-15 min. Afterward, cells were kept on ice in the
dark and washedwith ice cold RPMI/10% FCS supplemented with 100 mMTrolox or 20mMNAC to slow down cell metabolism. ROS
production was quantified by flow cytometry within the FITC-channel (Ex: 488nm/ Em: 519nm). The indicated mean fluorescence
intensity (MFI)-increase was normalized to untreated (or control treated) cells ((MFI treated – MFI untreated) / MFI untreated *
100). Extracellular H2O2-release was determined 2 h after treatment using the Amplex Red Hydrogen Peroxide/Peroxidase Assay
Kit (LIFE Technologies) according to the manufacturer’s instructions.
Annexin-Coated Vesicle Production
Lipid vesicles for initial binding experiments (Figure S3B) were generated by sonication. Phosphatidylcholine (PC, 1,2-dioleoyl-sn-
glycero-3-phosphocholine) and phosphatidylserine (PS, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine) (both purchased from Avanti
Lipids Polar) were mixed in a 5:1 ratio (PC:PS), supplemented with 50 mg/ml endotoxin-free OVA (invivogen) and suspended in Chlo-
roform (R99.5%, Sigma-Aldrich). After evaporation using a Concentrator 5301 with vacuum degassing equipment (Eppendorf), the
dry lipid/OVA-pellet was resuspended in DPBS (Ca2+ and Mg2+ included; DPBS2+; Sigma-Aldrich) and sonicated with a SONOPULS
HD 2070 device (Bandelin, at Cycle 5, 30% power) for 1 min. Lipid vesicles were centrifuged for 30 min by 18,000xg at 4C. After
removing the supernatant, lipid vesicles were resuspended in DPBS. For the preparation of annexin-coated vesicles, an aliquot of
lipid vesicles was diluted 1:5 in DPBS2+ supplemented with hAnxA1DN (50 mg/ml) and incubated over night at 4C on a roll shaker.
Unbound annexin was removed by centrifugation for 30 min at 18,000xg and 4C and following resuspension with DPBS2+. The
degree of annexin-loading was analyzed using anti-hAnx-FITC mAb generated in our laboratory (Weyd et al., 2013). Size-defined
PS-containing vesicles (400 nm) used for competition and functional experiments were generated by extrusion based on a protocol
obtained from W. Nickel and colleagues (Temmerman and Nickel, 2009). 18:1 (9-Cis) PC (DOPC), 18:1 PS (DOPS) and Cy5 labeled
phosphatidylethanolamine (Cy5-PE) (all from Avanti Polar Lipids) suspended in chloroform (Sigma-Aldrich) were mixed with a molar
ratio of 79% DOPC, 20% DOPS and 1% Cy5-PE in a 10 mL glass round-bottom flask. Lipids were handled in glassware to prevent
chloroform-mediated plastic contaminations. The lipid mixture was dried under vacuum for approximately 4 h. The remaining lipid
layer was dissolved in 50C pre-warmed PBS containing 10% sucrose (Merck) vortexing by short-time at a constant temperature
of 50C. Next, the lipid solution was frozen in liquid nitrogen and subsequently thawed ten times at 50C in order to exclude the for-
mation of multi-lamellar liposomes. An extruder with a 400 nm pore size membrane was used and the lipid mixture was pushed
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with DPBS and centrifuged at 18,000xg for 20 min at 4C. For the preparation of annexin-coated vesicles, 200ml of the lipid-vesicle
stock mixture diluted 1:5 in DPBS2+ and supplemented with hAnxA1DN (50 mg/ml) was incubated over night at 4C on a roll shaker.
Residual annexin was removed by centrifugation at 18,000xg for 90 min at 4C and the vesicles were resuspended in 200 ml DPBS2+.
The degree of annexin-loading was analyzed using anti-hAnx-FITC mAb generated in our laboratory (Weyd et al., 2013). Using BD
Trucount Tubes (BD Biosciences), we determined a vesicle concentration of about 30,000 vesicles/ml with approximately 2.6 pg
of coated hAnxA1DN/vesicle calculated semiquantitatively via WB (data not shown).
Attana Cell 200 Quartz Crystal Microbalance (QCM) Analysis
Attana Cell 200 is a dual channel, continuous-flow system for automated analysis of molecular interactions based on quartz crystal
microbalance (QCM) technology (Peiris et al., 2017; Salanti et al., 2015). To monitor binding interactions, one of the interacting mol-
ecules is immobilized on the sensor surface and the sample containing the other molecule of interest is injected over the immobilized
molecule. The signal output is given in frequency (Hz) and is directly related to changes in mass on the sensor surface. The negative
changes of resonance frequency are depicted. Dectin-1 expressing and Decitn-1 KO MM6 cells were immobilized on Attana sensor
surfaces using a capturing approach. Cell suspensions were centrifuged, and the cell pellets were rinsed briefly three times with PBS
(Thermo Fisher Scientific) to remove cell media. Cell pellets were then resuspended in PBS to a final density of 2x106 cells/ml. Immo-
bilization of the capturing molecule concanavalin A (ConA) on LNB carboxyl surfaces (3623-3001) was performed using Attana amine
coupling kit (3501-3001). 150 Hz of ConA was stably immobilized on the surfaces. Cells were captured on surfaces by incubating 105
cells in PBS for 30 min at RT. Following incubation, the cells were rinsed three times with 0.7 mL PBS at RT and stabilized in fresh 4%
(v/v) methanol-free formaldehyde (Thermo Fisher Scientific) for 15 min at 4C. Cell coverage was determined by staining cells with
3 mMDAPI (Merck) and visualized under fluorescent microscope (data not shown). Sensor surfaces were inserted in the biosensor or
stored under humidity at 4C in the dark until use. Interaction of the analytes with cell surfaces was assessed using Attana Cell
200 biosensor. Initial binding experiments were performed at a flow rate of 20 ml/min at 22C. All experiments were performed under
continuous flow of PBS (with CaCl2 + 0.1% FCS). A blank injection of PBS (with CaCl2 + 0.1% FCS) was performed before each an-
alyte injection. The blank injection was subtracted from the subsequent analyte injection to correct for baseline drift. One analyte at a
time was injected for 105 s over the cell surfaces. For kinetic experiments, four two-fold dilutions of each analyte were injected over
cell surfaces. Surface regeneration was carried out using a 30 s injection of glycine 10 mM (pH 2.2). Repeated injections of the same
analyte concentration resulted in identical binding curves, indicating that regeneration did not alter the binding capacity of the sur-
face. For competitive binding analysis the cells were coated on the sensor surface as described above. Single cycle kinetics and
competition assayswere performed at a flow rate of 10 ml/min at 22Cwith a continuous flow of PBS. Single cycle kinetic experiments
were performed to determine the saturation levels (Bmax values) of each analyte for the given surface. hAnxA1DN-coated vesicles
were injected into the flow cell over Dectin-1-expressing MM6 cells until saturation (Bmax). A mixture of hAnxA1DN-coated vesicles
and DZ (1:1) was further injected over the saturated surface. Experiments were also performed in the reverse order, i.e., injecting DZ
before the mixture. The frequency change in the sensor surface resonance (DF) during the binding experiments was recorded using
the Attester software (Attana AB) and the data were analyzed using the Evaluation (Attana AB) and TraceDrawer software (Ridgeview
Instruments) using 1:1 or 1:2 binding models to calculate the kinetic parameters including the rate constants (ka, kd), dissociation
equilibrium constant (KD) and the maximum binding capacity (Bmax). Simulation curves were generated using Evaluation
(Attana AB) software.
Production of the CLR-Fc Fusion Protein Library and ELISA Binding Experiments
The library of CLR-Fc fusion proteins was prepared as described previously (Maglinao et al., 2014). Briefly, murine splenic RNA was
reverse transcribed into cDNA using Reverse Transcriptase (New England Biolabs). The cDNA encoding the extracellular part of each
CLR was amplified by polymerase chain reaction (PCR) and was then ligated into the pFuse-hIgG1-Fc expression vector (Invivogen).
The CLR-Fc vector constructs were either stably transfected into CHO cells or transiently transfected using the FreeStyle Max
CHO-S Expression System (Thermo Fisher Scientific). Purification of the CLR-Fc fusion proteins from the cell supernatant was
performed using HiTrap Protein G HP columns (GE Healthcare). The purity of each CLR-Fc fusion protein was confirmed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent Coomassie staining, Western Blot using anti-
human IgG-HRP antibody (Dianova) as well as mass spectrometry. mAnxA1 (0,5 mg/well) and mAnxA5 (0,5 mg/well) were coated
on 96-well high binding plates (Greiner) overnight. After blocking with 1% BSA in PBS, 20 mg/mL of each CLR-Fc fusion protein
was incubated in lectin binding buffer (50 mM HEPES, 5 mMMgCl2, 5 mM CaCl2, pH 7.4) at RT for 2 h. The binding of CLR-Fc fusion
proteins was detected by an alkaline phosphatase-conjugated goat anti-hFc antibody (Dianova). Development was performed with
p-nitrophenyl phosphate (Thermo Scientific). For binding experiments in Figure 1B recombinant mAnxA1 or mAnxA5 (both 20 mg/ml)
were coated in coating buffer (BD Biosciences; supplemented with 5mM CaCl2) on 96-well plates (Greiner) overnight. After
blocking in PBS/2%BSA/5mM CaCl2 solution for 2h, mDectin-1 Fc fusion protein (solved in PBS/0.2%BSA/5mM CaCl2) was incu-
bated at RT for 2 h. The binding of mDectin-1 Fc to indicated annexins was detected by horseradish peroxidase-conjugated anti-mIg
(Thermo Fisher Scientific) using the substrate o-Phenylenediamine (Thermo Fisher Scientific). The absorbance by 490 nm was
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Surface Plasmon Resonance (SPR) Analysis
Binding analyses were carried out on a Biacore T100 instrument (GE Healthcare). CM5 sensor chips were functionalized with about
10,000 RUs of AnxA1 using the Amine Coupling Kit (GE Healthcare) according to the manufacturer’s recommendations. Kinetic
measurements were performed with the Biacore T100 Control software using the ‘Kinetics’ function. HEPES (10 mM) containing
CaCl2 (1 mM), MgCl2 (1 mM), 0.005% Tween pH 7,4 was used as running buffer and all measurements were performed at 25
C
and a flow rate of 30 ml min1. About 500 RUs of fusion proteins were captured and the indicated concentrations were passed
through using the standard parameters for association and dissociation times. Flow cells were regenerated with 10 mM glycine-
HCl pH 1.7 for 30 s. Kinetic evaluation of binding responses was performed with the Biacore T100 Evaluation software.
In Vivo Experiments
A total of 2x106 apoptotic S2-mAnxA1/OVA cells were injected (s.c.) into the right flank on day 0 and 7.Micewere sacrificed on day 14
and draining inguinal lymph nodes (dLN) were analyzed for OVA-specific CD8+ T cells using SIINFEKL-Dextramers (Immudex). Serum
was taken 1 day before the first injection, three days after the first injection and on day 14. The serum level of soluble urokinase
receptor (uPAR) was determined by ELISA (Ho¨lzel Diagnostika).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are shown as mean values ± standard deviation (s.d.) unless indicated otherwise. Sample numbers of data obtained from
animal experiments refer to the number of individual mice, as specified in the figure legends. Statistical analysis of data was
performed by unpaired or paired student’s t test as well as by Mann Whitney test, as indicated in the figure legends. If not otherwise
indicated, the significance of the difference compared with WT cells or control treated cells is depicted. The r values < 0.05 were
considered statistically significant using the GraphPad Prism software, as indicated in the figure legends.
DATA AND CODE AVAILABILITY
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